GPCRs-Targeted Drug Discovery Summit Leaderboard
  • Saturday, May 2, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Obesity & Weight Loss Drug Development Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 16

Author

Pharma Journalist 8769 posts 0 comments

Sanofi Replaces CEO Paul Hudson With Belén Garijo

Feb 13, 2026
French pharmaceutical group Sanofi announced a leadership transition after its board decided not to renew the mandate of Chief Executive Officer Paul Hudson. His final day leading the…
Read More...

Europe Approves Uplizna for Generalized Myasthenia Gravis

Feb 13, 2026
Biotechnology company Amgen has received authorization from the European Commission for UPLIZNA as an add-on therapy for adults with generalized myasthenia gravis (gMG) who test…
Read More...

FDA Clears Keytruda Combo for Resistant Ovarian Cancer

Feb 13, 2026
Pharmaceutical giant Merck & Co., Inc. — known internationally as MSD — has received U.S. regulatory approval for expanded use of its immunotherapy KEYTRUDA and the newer…
Read More...

Citius Expands LYMPHIR Access Across Europe With Uniphar Deal

Feb 13, 2026
Cancer-focused biotechnology company Citius Oncology, Inc. has entered an exclusive distribution agreement with international healthcare services group Uniphar to expand patient access…
Read More...

Madrigal Expands MASH Pipeline With Global siRNA Licensing Deal

Feb 13, 2026
Biopharmaceutical company Madrigal Pharmaceuticals, Inc. has signed an exclusive global licensing agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure…
Read More...

Ampersand Acquires Purna to Expand Global Pharma Services

Feb 13, 2026
Private equity firm Ampersand Capital Partners has announced the acquisition of contract development and manufacturing provider Purna Pharmaceuticals, signaling a strategic move to…
Read More...

Kincell Bio partners RegCell to advance Treg therapy trials

Feb 12, 2026
A new collaboration between U.S. cell-therapy manufacturer Kincell Bio and biotechnology innovator RegCell aims to accelerate the clinical development of a next-generation…
Read More...

Insilico, CMS Partner on AI Drug Discovery Programs

Feb 12, 2026
Clinical-stage biotechnology company Insilico Medicine and pharmaceutical commercialization group China Medical System Holdings have announced a multi-project collaboration aimed at…
Read More...

FDA Declines Review of Moderna mRNA Flu Vaccine Filing

Feb 12, 2026
Biotechnology company Moderna, Inc. said the FDA Center for Biologics Evaluation and Research has refused to begin reviewing its biologics license application for the investigational…
Read More...

Moderna Signs Mexico Pact for Local mRNA Vaccine Production

Feb 12, 2026
Biotechnology company Moderna, Inc. has signed a five-year strategic memorandum of understanding with the Government of Mexico, state manufacturer BIRMEX and pharmaceutical firm…
Read More...
Prev Next
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
GPCRs-Targeted Drug Discovery Summit
5th World ADC Summit South Korea
Extrahepatic Lipid-Based Nanoparticles Delivery Summit
World TPD & Induced Proximity Summit South Korea
Measuring Patient Engagement Summit
Investigative & Preclinical Toxicology Summit 2026
LEAP HR: Life Sciences West
Oligonucleotides for CNS Summit
R&D Procurement & Sourcing in Pharma Summit
In Vivo Cell Engineering & Gene Editing Summit
PFS & Injectable Drug Delivery West Coast
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
World Bispecific & T-Cell Engager Summit South Korea
TCR-Based Therapies Summit
PFS & Injectable Drug Devices East Coast
5th ADC Analytical Development Summit
Nasal Formulation & Delivery Summit
Peptide-Based Therapeutics Summit 2026
ALS Drug Development Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Gilead Completes $7.8 Billion Arcellx Acquisition Deal
  • EU Approves Rhapsido for Chronic Hives Treatment
  • Lilly to Acquire Ajax in $2.3 Billion Deal
  • Saphnelo Pen Approval Expands Lupus Treatment Access
  • BioMarin Completes $4.8 Billion Amicus Acquisition

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

Turning Biophysical Data into Confident Drug Discovery…

Targeted LNP Delivery Beyond the Liver: The Challenges…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.